PSMAfore Trial & Enzalutamide with 177Lu-PSMA-617 for mCRPC | Dr. Dharmender Malik | 05th Knowledge скачать в хорошем качестве

PSMAfore Trial & Enzalutamide with 177Lu-PSMA-617 for mCRPC | Dr. Dharmender Malik | 05th Knowledge

Discover insights from Dr. Dharmender Malik from Delhi on groundbreaking treatments for metastatic castration-resistant prostate cancer (mCRPC) during Day 1 of the 05th Knowledge Series for Genitourinary Cancers - Best of 2023. This event took place on May 11, 2024, at The Pride Aero City, Delhi, organized by the Cancer Research And Statistic Foundation, with support from the Institute of Pulmonology Medical Research & Development and Sunrise Oncology Centre. Dr. Malik presents: PSMAfore Phase 3 Trial: An investigation of [177Lu]Lu-PSMA-617 in taxane-naive patients with mCRPC, highlighting the potential of this radioligand therapy [ESMO 2023]. Enzalutamide and 177Lu-PSMA-617: A randomized Phase 2 trial focusing on poor-risk mCRPC, evaluating the efficacy of combining these treatments [ESMO 2023]. Stay informed about these cutting-edge treatments and their implications for improving outcomes in advanced prostate cancer. #ProstateCancer #mCRPC #PSMAforeTrial #177LuPSMA617 #Enzalutamide #CancerResearch #GenitourinaryCancers #Bestof2023 #Oncology #ESMO2023 #MedicalResearch #CancerCare #CRSF2024